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Diabetic cystopathy is a well-recognized complication of diabetes mellitus, which usually develops 
in middle-aged or elderly patients with long-standing and poorly controlled disease. It may have 
broad spectrum clinical presentations. Patients may be asymptomatic, or have a wide variety 
of voiding complaints from overactive bladder and urge incontinence to decreased bladder 
sensation and overflow incontinence. This review focuses on pathophysiological mechanisms 
responsible for urologic complications of diabetes and emphasizing on recent developments in 
our understanding of this condition. We also tried to shed some light on therapeutic modalities 
like behavioral, pharmacological, and surgical approaches.
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incontinency) and (b) reduced bladder outlet resistance (stress 
urinary incontinence). Mixed forms of these two forms are fre-
quently encountered in clinical practice (Michel et al., 2004). An 
overactive bladder originates from involuntary detrusor contrac-
tions during the filling phase of the micturition cycle; it can occur 
with or without incontinence, and frequently manifests as urinary 
frequency and nocturia.
PathoPhysiology of bladder dysfunction  
in diabetes
Diabetic bladder dysfunction refers to a group of bladder symp-
toms occurring in patients with diabetes mellitus. Diabetic bladder 
dysfunction presents in a spectrum of clinical symptoms represent-
ing a number of disorders ranging from bladder overactivity to 
impaired bladder contractility. Its prevalence has been estimated 
as being between 25 and 87% (Frimodt-Møller, 1980). However, 
since diabetes tends to occur in the elderly population, concurrent 
factors such as benign prostatic hyperplasia, neurological disor-
ders, and aging may also contribute to voiding dysfunction, and 
makes it difficult to assess the specific contribution of the diabetic 
state to voiding dysfunction in these patients. Diabetic cystopathy 
was used by Frimodt Moller in 1976 and refers to lower urinary 
symptoms due to diabetic neuropathy (Hill et al., 2008). Diabetic 
cystopathy is characterized by increased post voiding residual 
volumes and enhanced bladder capacity that is accompanied by 
decreased bladder sensation and contraction secondary to damage 
of visceral afferent fibers in the bladder wall (Kebapci et al., 2007). 
This insidious process causes gradual changes in patient’s voiding 
patterns, with a reduced desire to void, which usually occurs at a 
stored urine volume of 300–400 ml in healthy subjects (Smith, 
2006). These patients commonly experience difficulty in initiating 
and maintaining micturition. Therefore, voiding reflexes appear 
sluggish and an asymptomatic increase in bladder capacity and 
urinary retention occurs. On the other hand, diabetic bladder 
dysfunction can also present as an overactive bladder syndrome 
usually described as urgency, with or without incontinence, usually 
with urinary frequency and nocturia. Indeed bladder hypersensi-
tivity and hypercontractility is much more common than bladder 
background
Micturition is a highly coordinated process that starts with sens-
ing bladder filling, transferring data to the central nervous system 
processing center and efferent pathways resulting in the voiding 
response. Increasing the volume of the urinary bladder provokes 
afferent signals to the central nervous system. The molecular basis 
of distention sensing has not been fully clarified, but may involve 
the urothelium as a major factor during this process. The urothe-
lium represents the layer of epithelial cells lining the urinary tract 
between the renal pelvis and the urinary bladder. For many years, it 
was considered as a passive barrier for the passage of ions and sol-
utes, but currently is known to possess a number of novel features 
that allow it to respond to various physical and chemical stimuli, 
resulting in the release of various substances from the urothelial 
cells: these include ATP, nitric oxide (NO), substance P, acetylcho-
line, adenosine, antiproliferative factor, cytokines, various trophic 
factors, and prostanoids (Birder and de Groat, 2007).
During bladder filling at low volumes, low frequency impulses 
activate afferent nerves to signal the pontine storage and micturi-
tion centers, and stimulate sympathetic outflow via hypogastric 
and pudendal nerves. Released norepinephrine induces detrusor 
relaxation and enhances bladder compliance, which is mediated 
largely through β3-adrenergic receptors, while bladder outlet resist-
ance is enhanced by activation of α1-adrenergic receptors in the 
bladder neck, urethra and prostate (Michel and Vrydag, 2006). The 
somatic nerves also participate in the process of increasing blad-
der outlet resistance by releasing acetylcholine. Increasing urine 
volume will increase the frequency of afferent impulses, which in 
turn will shift efferent signaling from the pontine storage to the 
micturition center. This activates parasympathetic and inhibit sym-
pathetic outflow. The resultant acetylcholine stimulates detrusor 
muscle through mainly M3 muscarinic receptor subtypes (and also 
M2 receptors during pathophysiological situations) (Abrams et al., 
2006; Hegde, 2006).
Voiding dysfunction manifests in various forms including uri-
nary frequency, nocturia, urinary retention, and urinary incon-
tinence. The two most frequent causes of incontinence are (a) 
excessive pressure development by the bladder (urgency urinary Frontiers in Pharmacology | Cardiovascular and Smooth Muscle Pharmacology  November 2010  | Volume 1  |  Article 136  |  2
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perhaps also provide pharmacological strategy for the treatment 
of bladder dysfunction. However, it is important to consider that 
the studies of the effects of diabetes on detrusor contractility have 
yielded both increased (Tammela et al., 1994; Waring and Wendt, 
2000) and decreased contractility (Changolkar et al., 2005).
While there are many studies on the effect of oxidative stress on 
diabetic neuropathy, retinopathy, nephropathy, and cardiovascular 
dysfunction, there are relatively few reports on the role of oxidative 
stress on diabetic bladder dysfunction. Beshay and Carrier (2004) 
evaluated the oxidative status of the bladder in STZ-induced diabe-
tes in rats and concluded that the observed oxidative stress (reduc-
tion of catalase-like activity, increase in thiobarbituric acid reactive 
substance level and increases in the number of inducible NO syn-
thase positive cells) was not mediated by diuresis. Changolkar et al. 
(2005) measured increased lipid peroxidation and over expres-
sion of aldose reductase in alloxan induced diabetic rabbits. In 
the hyperglycemic state, the hexokinase pathway (which converts 
glucose into glucose-6-phosphate) becomes saturated and the affin-
ity of aldose reductase for glucose increases, causing an increased 
production and accumulation of sorbitol that is transformed to 
fructose by the action of sorbitol dehydrogenase. These reactions 
are accompanied by oxidation (and consumption) of NADPH to 
NADP+, and reduction of NAD+ to NADH. NADPH and NAD+ 
are necessary cofactors in redox reactions and their intracellular 
reduction leads to decreased synthesis of glutathione and other 
putative antioxidants such as taurine with an increased production 
of reactive oxygen species. Sorbitol also glycates nitrogen atoms on 
proteins (such as collagen) and the products of these glycations are 
referred to advanced glycation end products (Forbes et al., 2008). 
Daneshgari et al. (2009) provided unpublished evidence suggesting 
increased aldose reduction expression in human bladder smooth 
muscle cells under hyperglycemic conditions. The activation of 
the aldose reductase pathway also contributes to the activation of 
protein kinase C, a signal transduction protein that is altered in 
some tissues prone to diabetic complications (Changolkar et al., 
2005). Administration of ONO-2235, an aldose reductase inhibi-
tor, to STZ-induced diabetic rats caused (a) improved cystometric 
parameters such as voiding volumes, voiding fraction, and residual 
volumes and (b) restored the decreased genetic expression of blad-
der nerve growth factor and neurotrophin receptor p75
NTR, sug-
gesting a role for the polyol pathway in the genetic down regulation 
of nerve growth factor and p75NTR during cystopathy (Tong and 
Cheng, 2007). The p75NTR protein is one of two classes of cell sur-
face receptors for nerve growth factor that is expressed in sensory 
neurons. These findings are relevant as p75 positive nerve fibers 
have been identified in both human and rat bladder (Wakabayashi 
et al., 1995, 1996).
role of neuronal damage
Hyperglycemia can exert its toxic effects through neuronal dam-
age; included in the possible mechanism for this is activation of 
the polyol pathway (which results in accumulation of sorbitol 
and fructose), increases the production of free radicals, activates 
protein kinase C, and enhances the formation of advanced gly-
cated end products (Fedele, 2005). These metabolic derangements 
lead to axonal degeneration and impairment of nerve conduc-
tion, which later on manifest itself as bladder hyposensation. A 
hypo-contractility. More than half (∼55%) of diabetic patients have 
detrusor hyperreflexia, while another 23% have reduced detrusor 
contractility and a further 10% demonstrate detrusor areflexia 
with the remaining 11% showing indeterminate findings (Kaplan 
et al., 1995). Based on both animal studies and human findings, 
Daneshgari et al. (2009) presented the “temporal theory of diabetic 
bladder dysfunction” which proposes that hyperglycemia-induced 
polyuria plays a major pathophysiological role during the early 
stages of diabetes polyuria, causing compensatory bladder hyper-
trophy and associated myogenic and neurogenic alterations. This 
stage is compatible with findings of a hyperactive bladder during 
urodynamic evaluation when patients present with bladder storage 
concerns (urgency or urge incontinence). With time and accumu-
lation of toxic metabolites, decompensation of bladder tissue and 
function ensues, resulting in the classical signs and symptoms of 
diabetic cystopathy (hypocontractile detrusor or atonic bladder) 
in patients with urinary voiding problems.
Pathogenesis
The pathogenesis of diabetes induced bladder dysfunction is multi-
factorial. Alterations in detrusor muscle physiology, neuronal impair-
ment, and urothelial dysfunctions are considered as participating 
factors (Yoshimura et al., 2005).
role of detrusor muscle
Changes in the physiology of detrusor muscle are attributed to dif-
ferent mechanisms such as changes in intercellular connections 
and excitability, receptors density and distribution, alteration in 
intracellular signaling, and genetic changes (Yoshimura et al., 2005). 
However, there are several uncertainties and controversies related 
to the magnitude and the time course of these changes, and to our 
knowledge, nearly all of these conclusions are based on animal 
studies and with unknown relevance to human pathophysiology. 
The detrusor muscle shows an enhanced response to muscarinic 
agonists in diabetes. It may be due to an increased muscarinic 
receptor density (Saito et al., 1997) or increases in smooth mus-
cle sensitivity to calcium (Waring and Wendt, 2000). The latter 
effect may explain the increases maximal responses to carbachol, 
potassium, and electrical field stimulation occurring in the diabetic 
bladder (Waring and Wendt, 2000). Tong et al. (1999) reported a 
70% increase in the density of M2-receptors within 2 weeks of the 
induction of diabetes in rats. Likewise, Kubota et al. (2003) also 
measured enhanced β1-receptor mediated relaxation in detrusor 
smooth muscle isolated from rats 8–10 weeks after induction of 
type 1 diabetes with streptozotocin (STZ).
Glucosuria and osmotic diuresis both lead to increased bladder 
stretch, elevated intravesical pressure, leading to bladder hyper-
trophy, which upon decompensation can cause increased residual 
volume (Daneshgari et al., 2006). Additionally, bladder hypertrophy 
can also exacerbate oxidative stress (Satriano, 2007). The decompen-
sated bladder shows altered contractile characteristics and altered 
expression of muscarinic receptor subtypes also changed composi-
tion of myosin II isoforms. In addition, the increased expression 
of Rho A and Rho kinase in the hypertrophied bladder is associ-
ated with reduced myosin phosphatase activity (Peters et al., 2006), 
perhaps accounting for the augmented and prolonged responses 
to a depolarizing stimulus by KCl in hypertrophied bladder, and www.frontiersin.org  November 2010  | Volume 1  |  Article 136  |  3
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role of urothelium
The urothelium consists of at least three layers: basal, intermediate 
and apical, or superficial layer (umbrella cells). This barrier func-
tion of these cells is an early recognition of one of its functions. 
The urothelium is able to adjust itself to large variations in urine 
volume as the bladder fills and empties. At the cellular level, there is 
exocytosis and fusion of a subapical pool of discoidal shaped vesi-
cles with the apical plasma membrane of the superficial umbrella 
cells to result in increases in mucosal surface area (Wang et al., 
2005). The urothelium also acts as a sensor for controlling blad-
der function, and in this regards it releases many mediators that 
affects afferent nerves and so participates in a variety of abnor-
malities related to diabetic bladder dysfunction. Tight junctions 
and the presence of specialized lipid molecules and the uroplakin 
protein (a crystalline protein) in the superficial layer helps to sup-
port the passive barrier functions of this layer (Apodaca, 2004). 
The urothelium is also covered with a sulfated polysaccharide gly-
cosaminoglycan layer that diminishes bacterial adherence and acts 
as a non-specific defense mechanism against infection (Parsons, 
1994). Both local (infections, mechanical and chemicals trauma) 
and non-local insults (spinal cord injury) can interrupt the bar-
rier function of the urothelium. As a result, toxic substances can 
diffuse to the underlying tissues to induce symptoms of urgency, 
frequency, and pain during bladder filling and voiding (Birder and 
de Groat, 2007). These events can potentially change the levels of 
chemical mediators such as NO and ATP, which are important in 
epithelial integrity and proper functioning (Apodaca et al., 2003). 
The presence of P2X, P2Y receptors on the luminal surface of the 
bladder suggest the role for ATP as a communicating substance in 
bladder function (Burnstock, 2001; Birder et al., 2002a). Activation 
of purinergic receptors during bladder distension has signaling role 
throughout the bladder. For example, Wang et al. (2005) reported 
that increasing hydrostatic pressure stimulates the release of ATP 
from the urothelium, and that upon binding to P2X and possibly 
P2Y receptors on the luminal cells, activates Ca2+ and protein kinase 
A dependent second messenger cascades which leads to exocyto-
sis and membrane insertion at the apical poles of these cells. In 
addition, Brady et al. (2004) demonstrated a potential pathophysi-
ological role of purine expressing fibers in human subjects with 
neurogenic detrusor overactivity. Additional data suggests that 
ATP increases the currents evoked by capsaicin through activation 
of metabotropic P2Y receptors in a protein kinase C-dependent 
pathway. The large amounts of ATP released from damaged or 
sensitized cells in response to injury or inflammation can trigger 
the sensation of pain (Tominaga et al., 2001). The urothelium and 
bladder nerves have many receptors and ion channels in common, 
implying that injury or inflammation can alter the response of 
both urothelial cells and sensory afferents to nociceptive and other 
stimuli simultaneously (Yoshimura et al., 2005).
The bladder epithelium also synthesizes prostanoids such as 
prostaglandins F2α and E2, important mediators of bladder func-
tion under both normal and pathological conditions (Pinna et al., 
1994). There is an impaired endogenous prostaglandin release from 
epithelial preparations in type 1 diabetic rats, which may be related 
to for bladder abnormalities occurring during diabetes (Pinna et al., 
2000). Bradykinin and ATP and bradykinin increase the release of 
endogenous prostaglandins from the bladder epithelium,  suggesting 
decrease in acetylcholinesterase activity in bladder biopsies of 
diabetic patients may be due to axonal degeneration and impor-
tantly, Schwann cell proliferation occurs in an attempt to cause 
a regenerative rescue after demyelination or axonal degeneration 
(Van Poppel et al., 1998).
The decreased synthesis of nerve growth factor in the bladder 
or the defective transport of nerve growth factor to the lumbosac-
ral dorsal root ganglia is associated with diabetic neuropathy and 
bladder dysfunction (Brown et al., 2005). Nerve growth factor, a 
member of the neurotrophin factor family, is necessary for main-
taining the normal function of mature sensory and sympathetic 
neurons in addition to its ability to promote survival of the neurons 
during development (Thoenen and Barde, 1980; Levi-Montalcini, 
1987). Recent data also suggests a role for nerve growth factor in 
the processes of inflammation and pain (Steers and Tuttle, 2006). 
Diminished retrograde axonal transport of nerve growth factor has 
been implicated as a mechanism for inducing sensory neuropathy 
in diabetic animals (Hellweg and Hartung, 1990). Developments in 
gene therapy approaches have allowed dorsal root ganglia neurons 
to increased access of nerve growth factor; this was achieved by 
the injection of a herpes simplex virus (HSV) vector coding for 
the β subunit of nerve growth factor into the bladder to increase 
nerve growth factor levels in the dorsal root ganglia; there was 
a corresponding increase in bladder activity (Wang et al., 2005). 
HSV type 1 has several characteristics which make it an ideal gene 
transfer vector for treating diabetic cystopathy; first, it is a dou-
ble strand DNA virus that may infect and persist in a latent state 
within sensory neurons as part of the normal life cycle of the virus 
(Coffin et al., 1996). Second, HSV has a natural promoter system 
(the latency active pormoters LAP1 and LAP2), which may be used 
to drive long term transgenic expression in neurons of the periph-
eral nervous system (Goins et al., 1999); and third, it is possible to 
apply strong promoters (such as the human cytomegalovirus, the 
immediate early gene promoter HCMV IEp), to achieve high level 
transient transgenic expression in the peripheral as well as in the 
central nervous system (Fink et al., 1996).
In addition to cystopathy, diabetic neuropathy can also affect 
other organs including the gastrointestinal tract. Gastrointestinal 
complications of diabetes (constipation, impaired rectal sensation, 
and/or fecal incontinence from abnormal internal anal sphincter 
tone) are particularly important to lower urinary tract perform-
ance (Birnbaum et al., 2003). Pressure from an over-distended 
bladder can reflexively inhibit parasympathetic activity, a stimu-
lus for fecal retention and soiling. On the other hand, straining 
to defecate can affect pelvic floor muscles and lead to rectocele, 
cystocele (in women), and an increased risk of stress incontinence 
and incomplete bladder emptying (Manning et al., 2003; Moore 
et al., 2003).
It should also be mentioned that both somatic and/or auto-
nomic neuropathy participate in vesicourethral dysfunction. An 
association of bladder dysfunction and autonomic neuropathy as 
had been detected in a group of 53 diabetic patients by using the 
“sympathetic skin response test” (Ueda et al., 1997). Other reports 
also suggest that the “tibial somatosensory evoked potential” is an 
easily performed test that has a good correlation with abnormal 
urodynamics in diabetic patients with or without lower urinary 
tract symptoms (Rapidi et al., 2006).Frontiers in Pharmacology | Cardiovascular and Smooth Muscle Pharmacology  November 2010  | Volume 1  |  Article 136  |  4
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being attributed to diabetes including polyuria. Nearly 25–50% of 
patients do not complain of voiding problems unless specifically 
asked (Frimodt-Møller, 1978). Understanding the symptoms expe-
rienced by the patient is an important initial step. Since diabetic 
bladder dysfunction is a slowly progressing and insidious disease, 
patients can overlook early signs and symptoms. Ueda et al. (1997) 
examined 53 asymptomatic diabetic patients and found that upon 
careful questioning, nearly 40% expressed a voiding complaint. 
The classic symptoms of reduced bladder contractility are usually 
manifested as hesitancy, weak stream, dribbling, sense of incom-
plete emptying, leaking with increased abdominal pressure, and 
infrequent voiding (Hunter and Moore, 2003). However, more 
recent clinical studies show considerable diversity in the signs and 
symptoms of this disease. A urological study done by Starer and 
Libow (1990) in a sample of 23 elderly diabetic patients reported 
that only 17% presented with urinary retention (which is consist-
ent with the classical definition of diabetic cystopathy), while 76% 
had involuntary bladder contractions presenting as urgency and/
or nocturia. These findings are important considerations when 
choosing therapeutic modalities for elderly diabetic patients. A 
detailed history of the patient’s symptoms will guide management 
strategies, while additional information about their diabetes and 
glycemic control may provide information about the severity of 
disease. Past medical and surgical history and use of drugs that 
could affect the bladder function or produce functional limitation 
should be obtained. Since diabetic cystopathy is s a manifestation 
of autonomic neuropathy, screening for other signs of autonomic 
dysfunction particularly heart rate and orthostatic hypotension 
could be helpful (Hunter and Moore, 2003).
WorkuP
The history taking and physical examination of diabetic patients 
who have signs and symptoms of bladder dysfunction should be 
followed by laboratory workup tests. The rate of bacterial cystitis is 
higher in diabetic subjects, so urinalysis and culture with some addi-
tional biochemical tests for the assessment of diabetic control and 
also screening for end organ damage (such as serum glucose, glyco-
sylated hemoglobin, urea, and creatinine) should be ordered. Other 
diseases and conditions that can induce or aggravate vesicourethral 
dysfunction should also be considered. Thus it is important to rule 
out neurological disorders, especially cerebrovascular accidents, or 
lumbar disk disorders that can also cause urinary symptoms mim-
icking those found in diabetes mellitus. Examination for benign 
prostatic hypertrophy, anal sphincter tone, saddle anesthesia, and 
bulbocavernosus reflex is important, while examination of females 
should also include a complete urogynecological examination to 
rule out pelvic organ prolapse such as cystocele or other forms of 
pelvic prolapse; an assessment of the integrity of pelvic floor muscle 
should be done in females. Urodynamic studies are key components 
of patient examination, and can include a simple cystometrogram, 
simultaneous pressure/flow studies, uroflow, sphincter electromy-
ography, and evaluation of leak point pressures plus measurement 
of post void residue (Goldman and Appell, 1999).
A study by Lee et al. (2004) compared the voiding behavior of 
194 women with type 2 diabetes with that in 162 control women, 
using a lower urinary tract symptoms questionnaire and uroflow-
metry. They found that diabetic women had significantly higher 
the presence of both bradykinin receptors and purinergic receptors 
not only in the detrusor smooth muscle but also in the epithelial 
layer (Pinna et al., 2000). Bradykinin induced release of prostag-
landin E2 has been demonstrated in human urothelial cell cultures 
(Zenser et al., 1988).
The prevalence of bacteriuria and urinary tract infections is 
much higher in diabetic women compared to healthy individuals 
(Stapleton, 2002). This process is initiated by the colonization of 
the vaginal and periurethral epithelium and then ascension to the 
bladder or bacteremia will occur. Type 1 fimbriated E. coli have a 
higher affinity for epithelial cells of diabetic patients – they bind 
to uroplakin proteins on the luminal surface of bladder and then 
invade the bladder wall (Geerlings et al., 2002). Internalization of 
the micro-organisms and formation of intracellular colonies in 
umbrella cells may be a pathway to chronic urinary tract infection 
(Schilling and Hultgren, 2002).
Nitric oxide is synthesized by a family of enzymes known as 
NOSs [endothelial (eNOS), inducible (iNOS), and neuronal 
(nNOS)]. There is activation of NOS in the urothelium, smooth 
muscle, striated muscle, nerves, and blood vessels of the lower uri-
nary tract of humans and of laboratory animal models. The smooth 
muscle relaxing effect of NO on detrusor muscle has been shown 
in animal studies (Mumtaz et al., 2000). For example, Birder et al. 
(2002b) reported that the activation of β-adrenoceptors stimulates 
the adenylate cyclase pathway in epithelial cells of rat bladder, and 
this increases intracellular Ca
2+ and so triggers NO production and 
release. NO may also have a regulatory effect in bladder blood sup-
ply during the voiding and filling phases (Ho et al., 2004). In addi-
tion, there may also be a protective effect of NOS inhibition with 
N-nitro-l-arginine (L-NAME) on ischemia reperfusion induced 
apoptosis in the rat bladder (Saito and Miyagawa, 2002). NO also 
plays an important role in the relaxation of the urethra and ure-
thral sphincter (Mamas et al., 2003). Inhibitors such as L-NAME 
can attenuate urethral smooth relaxation while NO donors could 
have therapeutic roles in the treatment of sphincter spasticity and 
obstruction (Haab, 2000; Reitz et al., 2004). It has long been known 
that NO may have a role in non-adrenergic, non-cholinergic neu-
rotransmission in the lower urinary tract, a suggestion that was 
strengthened by immunohistochemical evidence for NOS activity 
in the striated muscles of human urethral sphincters (Mamas et al., 
2003). Stimulation of the parasympathetic input to the urethra 
elicits NO-dependent urethral smooth muscle relaxation in rats 
(Mumtaz et al., 2000).
Increases in NOS activity in the urothelium, smooth muscle, 
and intramural neurons of the bladder neck and urethra of dia-
betic rabbits are not accompanied by changes in intracellular cGMP 
(Mumtaz et al., 2000). Moreover, in spite of increased NOS activity, 
NO-dependent bladder outlet and urethral relaxation was impaired 
in diabetic individuals. These findings suggest that enhancement 
of NO-cGMP coupling could be an additional therapeutic option 
(Birder et al., 2002b).
diagnosis
history, signs, and symPtoms
Both physicians and patients are equally concerned about a vari-
ety of diabetic complications such as neuropathy, retinopathy, or 
nephropathy, and on the other hand, bothersome bladder functions www.frontiersin.org  November 2010  | Volume 1  |  Article 136  |  5
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Recent research has focused on the supplementation of diet with 
thiamine or cyclohexanoic long chain fatty acids. Some encouraging 
results show that these compounds can diminish or even prevent 
diabetic cystopathy (Suzuki et al., 2006; Yenilmez et al., 2006; Saito 
et al., 2007). Patients must be educated to minimize nocturnal 
polyuria, by confining most fluid intake to the morning or early 
afternoon, avoiding bladder irritants such as caffeinated beverages, 
and void before going to bed (Hunter and Moore, 2003). Alcohol is 
also a diuretic, so patients should expect greater urinary volumes 
if they consume it. Attention should also be given to maintaining 
regular bowel habits by increasing fiber consumption via appro-
priate foods or supplements, especially in constipated patients. 
Emphasizing better glucose control, improving blood pressure 
control, and encouraging cigaret-smoking cessation are also very 
important components in such patients (Ho et al., 2007).
Pelvic floor exercises, or Kegel exercises, are useful to strengthen 
the pubococcygeus muscles of the pelvic floor, which support the 
structures of the bladder and urethra. These exercises are helpful 
in stress, urge and mixed incontinence. Patients may be given some 
simple instructions to identify and contract appropriate muscles. 
One technique is to insert a finger into the vagina, or rectum (in 
men): then the patient is encouraged to tighten the muscles around 
the finger as if holding back urine. The abdominal and thigh mus-
cles should stay relaxed. Referral to a physical therapist specializing 
in pelvic floor physical therapy may help patients learn the correct 
technique. A systematic review of 96 randomized controlled trials 
and 3 systematic reviews concluded that pelvic floor muscle training 
and bladder training resolved urinary incontinence in most women 
(Shamliyan et al., 2008).
Patients should be encouraged to void frequently (every 2–4 h) 
and to use a double voiding technique. This technique helps to 
prevent urinary incontinence by performing two micturitions, 
which will empty the bladder more effectively. In patients with a 
hypotonic or atonic bladder, Crede’s manual compression of the 
lower abdomen or the Valsalva’s maneuver can also be useful in 
facilitating micturition (Fedele, 2005). However, clean intermittent 
self-catheterization is the primary therapy for impaired or absent 
detrusor muscle activity (Ho et al., 2007). There is no evidence to 
support the choice of either sterile or clean techniques in patients 
with diabetes (Hunter and Moore, 2003). The interval between 
catheterizations should be designed to maintain a residual volume 
of less than 400 cc and to avoid incontinence. Many patients are 
reluctant to use a catheter because they are uncomfortable with the 
anatomy, or find it painful. Patients who develop recurrent urinary 
tract infections are started on antimicrobial prophylaxis therapy.
Pharmacological treatments
Antimuscarinic agents represent the cornerstone of treatment 
for patients who present with an overactive bladder. These agents 
inhibit the binding of acetylcholine at muscarinic M2 and M3 recep-
tors on detrusor smooth muscle cells and other structures within 
the bladder wall, thus, reducing the contractions of the detrusor 
muscle and controlling involuntary detrusor contractions without 
disturbing normal voiding. However, there is some uncertainty 
about the effectiveness of this group of drugs. A systematic review 
of randomized controlled trials showed that the differences between 
anticholinergic drugs and placebo, in terms of patient perceived 
nocturia scores, weaker urinary streams, reduced voided volumes, 
and lower maximal flow rates. Residual urine volume (100 ml or 
greater) occurred in a significantly higher proportion of diabetic 
subjects (13.9 vs. 1.8% of controls). Likewise Ho et al. (2010) ana-
lyzed the urodynamic findings of 94 diabetic patients with a variety 
of lower urinary tract symptoms. Over active bladder was seen in 
36.2% of diabetics with a higher percentage of increased bladder 
sensation and detrusor overactivity, lower peak flow rate, greater 
post void residue volume, and lower bladder voiding efficiency. 
On pressure flow studies, the over active bladder group had a 
higher percentage of bladder outlet obstruction (26.5 vs. 6.7%). 
Since they had excluded women with other causes of bladder out-
let obstruction such as anti-incontinence surgery or pelvic organ 
prolapse, it is likely that the majority of bladder outlet obstruc-
tion in this group of patients was due to functional obstruction 
(sometimes termed sphincter dyssynergia; Kitami, 1991). Finally, 
Kitami (1991) evaluated vesicourethral dysfunction in 173 diabetic 
patients (78 male, 95 female). In his study, diabetic patients showed 
a range of vesicourethral dysfunctions such as overactive blad-
der (14.5%), low compliance bladder (11%), and loss of detrusor 
external sphincter coordination (31.7%). The study also showed a 
significant correlation between the extent of pyuria and ectasis of 
the upper urinary tract with residual urine volume and detrusor 
external sphincter coordination. With time and with decompen-
sation of THE bladder, the post void residual volume increases 
and this can lead to long-standing chronic urinary tract infection 
and irreversible bladder fibrosis. Fibrotic obstruction of uretero-
vesical junction causes hydroureteronephrosis that is followed by 
renal impairment. Thus proper management of diabetic patients 
in the early stages of the disease is of paramount importance as 
this can prevent or delay many of the complications of bladder 
dysfunction.
treatment modalities
The choice of a specific treatment of diabetic cystopathy depends on 
the urodynamic abnormalities found. Management goals include 
relief of symptoms, prevention and treatment of urinary tract infec-
tions, and adequate bladder emptying. In this regard, the man-
agement strategies can be grouped into three classes: behavioral, 
pharmacological, and surgical.
behavioral modalities
As a first stage of treatment, non-invasive strategies should be 
considered. A large, randomized clinical trial study of prediabetic 
subjects performed by the Diabetes Prevention Program Research 
Groups showed that lifestyle modification is more effective than 
metformin in reducing the incidence of diabetes in high risk pop-
ulation (Knowler et al., 2002). Thus weight reduction improves 
urinary incontinence in obese women and should be considered 
an initial step for moderately obese women as part of non-surgical 
treatment of incontinence (Subak et al., 2002). A recent study ana-
lyzed the results of the Diabetes Prevention Program study and 
concluded that life style modification consisting of a 5–10% weight 
reduction substantially lowered symptoms of incontinence (Brown 
et al., 2006). Other recommendations may include changes in diet, 
assessing the amount and timing of fluid intake, and bladder and 
pelvic muscle training.Frontiers in Pharmacology | Cardiovascular and Smooth Muscle Pharmacology  November 2010  | Volume 1  |  Article 136  |  6
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In general, anticholinergic drugs cause dry mouth, blurred vision, 
somnolence, dizziness, cognitive problems, and constipation. Close 
angle glaucoma is a contraindication for anticholinergic treatment. 
The most common side effect and reason for non-compliance is 
dry mouth (Chapple et al., 2005). Patients need to be monitored for 
retention and post void residual on follow up visits despite reports 
of symptomatic improvement.
Imipramine is a tricyclic antidepressant that has been exten-
sively used in the treatment of over active bladder, and appears 
useful in managing diabetic autonomic dysfunction such as 
incontinence (Duby et al., 2004). This drug inhibits the re-up-
take of noradrenaline and serotonin by adrenergic nerve end-
ings, resulting in increased contractile effects of noradrenaline 
on urethral smooth muscle and enhanced detrusor muscle 
relaxation. In addition to blocking amine re-uptake, imipramine 
also has a direct smooth muscle relaxing effect that could con-
tribute to increased storage function. Chronic administration 
of imipramine has shown to be clinically effective in improv-
ing functional bladder capacity by a reduction in detrusor 
pressure concurrent with an increased resting sphincter tonus 
(Hunsballe and Djurhuus, 2001). However, tricyclic antide-
pressants, including imipramine, can cause serious side effects 
(including increased dependency and some cardiovascular risks) 
a careful consideration should be given to the risks and benefits 
of this drug in the management of incontinence and over active 
bladder is needed.
Sadly, pharmacotherapy has a limited role in the treatment of 
detrusor areflexia. Attempts have been made to simulate detrusor 
muscle by administration of parasympathomimetic drugs. Such 
drugs stimulate the autonomic effector cells and postganglionic 
parasympathetic receptors resulting in increased intravesical pres-
sure and decreased bladder capacity. The side effects of cholinergic 
agents (such as sweating, salivation, tachycardia, and flushing) 
limit the daily use of them. In patients with consistent residual 
volumes of over 100 mL but not exceeding 500 mL, treatment 
with bethanechol (10–20 mg orally three to four times a day) 
may be beneficial. This drug has relatively selective actions on 
the urinary bladder and has also been used to facilitate reflex 
bladder contraction in patients with suprasacral spinal cord 
injury (Wein et al., 1992). If side effects occur, booster doses of 
bethanechol (30–60 mg orally twice weekly) have proved equally 
effective (Ziegler, 2001). Carbachol chloride, which has additional 
ganglion stimulating properties, enhances bladder motility (Wein 
et al., 1992).
Alpha-methyl-dopa and phenoxybenzamine have been stud-
ied as other therapeutic options. There were two reasons for 
trying these drugs. First, the bladder neck and posterior urethra 
contain a predominance of alpha adrenergic receptors. Agents 
that block or depress their function promote bladder neck and 
urethral relaxation. Second, postganglionic sympathetic fibers 
regulate transmission of cholinergic discharge of the pelvic para-
sympathetic ganglia. Blockade of this effect facilitates bladder 
contraction by improving the transmission at the pelvic para-
sympathetic ganglia. However, these agents have provided limited 
clinical benefits and are rarely used (Raz et al., 1977; Tammela, 
1986) (Figure 1).
cure or improvement, was smaller than expected from clinical expe-
riences (Herbison et al., 2003). On the other hand, a meta-analysis 
of 56 randomized controlled trials found that antimuscarinics are 
safe and efficacious, and all of them except oxybutynin immedi-
ate release (IR) are well tolerated. The extended release (ER) form 
of tolterodine is the only formulation with fewer total treatment 
discontinuations compared with placebo (Chapple et al., 2005). 
Tolterodine and oxybutynin are clinically equipotent in treating 
detrusor overactivity in specific severity groups of patients, although 
the urodynamic effects are somewhat different (Giannitsas et al., 
2004). A comparison between newer antimuscarinic (solifenacin, 
darifenacin) and the more established agents shows similar efficacy. 
In comparisons between IR and ER formulations, the latter showed 
more advantages both in terms of efficacy and safety (Novara et al., 
2008). However, another randomized, double blind study suggests 
a superiority of solifenacin over an ER formulation of tolterodine 
(Chapple et al., 2007).
Trospium chloride is an anticholinergic agent with predomi-
nantly peripherally acting non-selective antimuscarinic activity. 
This drug has three unique pharmacokinetic properties; it is a 
quaternary ammonium compound, which minimizes its central 
nervous system penetration and therefore has fewer adverse cog-
nitive effects. Second, it is not metabolized by the cytochrome 
P450 system, resulting in a reduced tendency for drug–drug 
interactions; and third, it is excreted in urine in the form of 
the active parent compound, providing for an early onset local 
effect. It has shown promising effects in the treatment of overac-
tive bladder and currently is being considered as an alternative 
for patients who do not tolerate oxybutynin well (Biastre and 
Burnakis, 2009). Some studies report that trospium has supe-
rior features compared to tolterodine in terms of decreasing the 
frequency of micturition and incontinence episodes (Junemann 
and Al-Shukri, 2000).
Fesoterodine is an anticholinergic drug that functionally acts 
as a prodrug. It is rapidly and extensively hydrolyzed by non-
specific esterases to 5-hydroxymethyl tolterodine (5-HMT), so 
bypassing the CYP system [although cytochrome P450 (CYP) 
is involved in the subsequent inactivation of the active metabo-
lite]. The conversion is rapid and virtually complete, such that 
after oral dosing only the metabolite, and not the parent com-
pound, can be detected in patient plasma. This active metabolite 
is responsible for the antimuscarinic activity of fesoterodine, and 
is the active metabolite of tolterodine. Tolterodine is converted 
to 5-HMT by the CYP2D6 enzyme system. Thus, the efficacy of 
conversion of tolterodine to 5-HMT is can vary with the activ-
ity and expression of CYP2D6 in individual patients (Ellsworth, 
2009). The efficacy and safety of fesoterodine in overactive blad-
der treatment appears to bet similar to that of tolterodine. The 
available data does not show a substantial advantage of fesot-
erodine over tolterodine ER in either efficacy or safety (Tzefos 
et al., 2009).
Propiverine hydrochloride is an agent that has combined 
antimuscarinic and calcium antagonistic action. Inhibition of cal-
cium influx that underlies musculotropic spasmolysis is an impor-
tant consideration in treating an overactive bladder and may result 
in a reduction in the frequency of micturition (Lee et al., 2010).www.frontiersin.org  November 2010  | Volume 1  |  Article 136  |  7
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nerve foramen (S3) for a test period of 1–4 weeks. If the patient 
improve more than 50% based on objective and subjective evalu-
ation, then stage two or permanent step, in which an implantable 
pulse generator is placed in the soft tissue of the patient’s buttock 
(Daneshgari and Moy, 2005). In a study on diabetic patients by 
Daniels et al. (2010) they showed a success rate of 69.2% in urge 
incontinence, 85.7% of those with urgency-frequency, and 66.7% 
of those with urinary retention which was not different from non-
diabetic cohorts. However, diabetic patients had a higher incidence 
of device explantation due to infection (37.5 vs. 25.5%).
summary
Diabetic bladder dysfunction is relatively common and can have 
different manifestations from detrusor instability to poor blad-
der sensation and contraction. Diabetic neuropathy plus detrusor 
muscle and urothelial dysfunctions all have some role in patho-
physiology. Urodynamic evaluation is the cornerstone of diagnosis 
and determines the actual type of bladder dysfunction and the 
therapeutic strategies. As non-pharmacological treatments, life style 
modifications such as, weight reduction, diet changes, amount, and 
timing of fluid intake and pelvic muscles training is recommended. 
For those who present with detrusor overactivity anticholinergic 
drugs may be an option, while pharmacotherapy has a limited role 
in the treatment of detrusor areflexia. Rarely, surgical intervention 
could render beneficial effects. Gene therapy and tissue engineering 
have opened new horizons with exciting promise.
surgical treatments
Patients with the classical signs of diabetic cystopathy (impaired 
detrusor contractility) but who do not benefit from non-phar-
macological and pharmacological interventions are candidates for 
surgical intervention. The aim of these procedures is to minimize 
the risk of urinary tract infection. Vesical neck resection, which is 
performed through a transurethral rout and leaves the external 
sphincter intact to preserve urinary continence, has been advocated 
by some authors (Zincke et al., 1974). The rationale for this proce-
dure is based on resistance reduction in the presence of a hypotonic 
bladder. There is, however, a risk of retrograde ejaculation in men 
and cystourethrocele in women. In addition, the function of the 
external sphincter may be impaired due to diabetic neuropathy and 
also lead to urinary incontinence (Frimodt-Møller and Mortensen, 
1980). Bladder outlet resistance may also be reduced by selective 
pudendal nerve block. In this procedure, a solution of 1% lidocaine 
is used initially to determine if micturition is improved and post 
voiding residual volume decreased, before a unilateral pudendal 
neurectomy is considered as a treatment option (Fedele, 2005).
Sacral neuromodulation (SNM) is another approved method 
for urinary urge incontinence, urge-frequency incontinence, and 
non-obstructive urinary retention refractory to non-surgical treat-
ment. In this method a small wire lead is placed in the S3–S4 sacral 
foramen, which is then connected to an implantable pacemaker. 
Usually this method is performed in two steps; the first stage is a 
trial stage in which a fine wire lead is introduced into the sacral 
Figure 1 | Treatment levels for diabetic bladder.Frontiers in Pharmacology | Cardiovascular and Smooth Muscle Pharmacology  November 2010  | Volume 1  |  Article 136  |  8
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